Vertex Pharmaceuticals (VRTX) Set for Painless Gains After FDA Approval
Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare ...
Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors
This was the stock's second consecutive day of losses.
Nasdaq5d
Should You Pick VRTX Stock At $450?
Vertex Pharmaceuticals stock (NASDAQ: VRTX) is trending higher after the U.S. FDA approved Journavx – an oral non-opioid pain medication. This is a big win for Vertex, given that Journavx can ...
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
Buying $100 In VRTX: If an investor had bought $100 of VRTX stock 20 years ago, it would be worth $4,232.95 today based on a ...
stocknews4d
3 Genomic Stocks at the Forefront of Precision Medicine
Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector ...
Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors
The stock's fall snapped a four-day winning streak.
Nasdaq4d
Validea Detailed Fundamental Analysis - VRTX
VERTEX PHARMACEUTICALS INC (VRTX) is a large-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the ...
ETF Daily News5d
Vertex Pharmaceuticals (NASDAQ:VRTX) Receives “Overweight” Rating from Cantor Fitzgerald
Cantor Fitzgerald currently has a $480.00 price target on the pharmaceutical company’s stock. VRTX has been the topic of a number of other reports. Wells Fargo & Company cut shares of Vertex ...